Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Morphic Holding files $400M mixed securities shelf  16:11
07/01/20
07/01
16:11
07/01/20
16:11
MORF

Morphic Holding

$26.21 /

-0.72 (-2.67%)

 
ShowHide Related Items >><<
MORF Morphic Holding
$26.21 /

-0.72 (-2.67%)

MORF Morphic Holding
$26.21 /

-0.72 (-2.67%)

07/22/19 Jefferies
Morphic Holding initiated with a Buy at Jefferies
07/22/19 Wells Fargo
Morphic Holding initiated with an Outperform at Wells Fargo
07/22/19 BMO Capital
Morphic Holding initiated with an Outperform at BMO Capital
  • 12
    Feb
Hot Stocks
Morphic Holding presents preclinical data on MORF-057 » 07:37
06/29/20
06/29
07:37
06/29/20
07:37
MORF

Morphic Holding

$25.53 /

-1.63 (-6.00%)

Morphic Therapeutic…

Morphic Therapeutic announced a presentation highlighting Morphic's product candidate MORF-057 at the 2020 Digestive Disease Week virtual event. The new data presented at DDW expand on Morphic's recent oral presentation at the 15th Congress of the European Crohn's and Colitis Organisation, which support MORF-057's development as a potent, selective, and orally available small molecule inhibitor of the integrin alpha4beta7, a validated target for the treatment of inflammatory bowel disease. The data presented at DDW demonstrate MORF-057's inhibition of alpha4beta7-expressing lymphocyte migration to the gut, which is a fundamental contributor to IBD. In mice, its inhibitory activity demonstrated potency comparable to an anti-alpha4beta7 antibody. In non-human primate models, MORF-057 demonstrated important proof of mechanistic activity by driving accumulation of mucosal homing alpha4beta7-high expressing T cells in the peripheral blood, in an analogous manner to the approved anti-alpha4beta7 antibody, vedolizumab. Importantly, a MORF-057 analog demonstrated greater than90% receptor occupancy of alpha4beta7 in NHPs, providing an important indicator of the product candidate's target engagement. In biochemical assays MORF-057 demonstrated high selectivity over a broad panel of integrins. These results were consistent in cell adhesion assays, where MORF-057 showed greater than 3,000-fold targeted selectivity of alpha4beta7 integrin over its nearest family members, including alpha4beta1. MORF-057 was designed to achieve high selectivity for alpha4beta7 over alpha4beta1 to help prevent unwanted localized immune suppression potentially leading to certain adverse opportunistic infections. In contrast to small molecule or antibody inhibitors of alpha4beta1, a MORF-057 analog did not show a statistically significant increase in lymphocytes in mice in these studies.

ShowHide Related Items >><<
MORF Morphic Holding
$25.53 /

-1.63 (-6.00%)

MORF Morphic Holding
$25.53 /

-1.63 (-6.00%)

07/22/19 Jefferies
Morphic Holding initiated with a Buy at Jefferies
07/22/19 Wells Fargo
Morphic Holding initiated with an Outperform at Wells Fargo
07/22/19 BMO Capital
Morphic Holding initiated with an Outperform at BMO Capital
  • 12
    Feb
Conference/Events
BMO Capital to hold a virtual conference » 08:41
06/23/20
06/23
08:41
06/23/20
08:41
ANTM

Anthem

$265.10 /

-1.41 (-0.53%)

, IMUX

Immunic

$14.17 /

+0.36 (+2.61%)

, SRRK

Scholar Rock

$19.09 /

+0.27 (+1.43%)

, EHC

Encompass Health

$63.73 /

-0.48 (-0.75%)

, FLXN

Flexion

$12.71 /

-0.02 (-0.16%)

, REGN

Regeneron

$627.91 /

-15.055 (-2.34%)

, SLGL

Sol-Gel Technologies

$8.44 /

+0.2 (+2.43%)

, MORF

Morphic Holding

$29.62 /

+2.45 (+9.02%)

, MNK

Mallinckrodt

$2.91 /

+0.355 (+13.89%)

, ETTX

Entasis Therapeutics

$2.99 /

-0.035 (-1.16%)

, AGTC

Applied Genetic

$6.39 /

+0.255 (+4.16%)

, HZNP

Horizon Therapeutics

$52.52 /

+2.545 (+5.09%)

, BBIO

BridgeBio

$33.07 /

+1.06 (+3.31%)

, AQST

Aquestive Therapeutics

$5.42 /

+0.01 (+0.18%)

, BTAI

BioXcel Therapeutics

$56.96 /

+4.27 (+8.10%)

, CNC

Centene

$63.09 /

-1.08 (-1.68%)

, LNTH

Lantheus

$13.99 /

-0.58 (-3.98%)

, SDGR

Schrodinger

$75.65 /

+0.49 (+0.65%)

, SCPH

scPharmaceuticals

$7.55 /

+0.35 (+4.86%)

, PHAT

Phathom Pharmaceuticals

$45.36 /

-0.635 (-1.38%)

, HUM

Humana

$379.31 /

-1.3 (-0.34%)

, HARP

Harpoon Therapeutics

$18.18 /

-0.02 (-0.11%)

Prescriptions for Success…

Prescriptions for Success Healthcare Virtual Conference will be held on June 23 at 9 am. Webcast Link

ShowHide Related Items >><<
SRRK Scholar Rock
$19.09 /

+0.27 (+1.43%)

SLGL Sol-Gel Technologies
$8.44 /

+0.2 (+2.43%)

SDGR Schrodinger
$75.65 /

+0.49 (+0.65%)

REGN Regeneron
$627.91 /

-15.055 (-2.34%)

PHAT Phathom Pharmaceuticals
$45.36 /

-0.635 (-1.38%)

MORF Morphic Holding
$29.62 /

+2.45 (+9.02%)

MNK Mallinckrodt
$2.91 /

+0.355 (+13.89%)

LNTH Lantheus
$13.99 /

-0.58 (-3.98%)

IMUX Immunic
$14.17 /

+0.36 (+2.61%)

HZNP Horizon Therapeutics
$52.52 /

+2.545 (+5.09%)

HUM Humana
$379.31 /

-1.3 (-0.34%)

HARP Harpoon Therapeutics
$18.18 /

-0.02 (-0.11%)

FLXN Flexion
$12.71 /

-0.02 (-0.16%)

EHC Encompass Health
$63.73 /

-0.48 (-0.75%)

CNC Centene
$63.09 /

-1.08 (-1.68%)

BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

BBIO BridgeBio
$33.07 /

+1.06 (+3.31%)

AQST Aquestive Therapeutics
$5.42 /

+0.01 (+0.18%)

ANTM Anthem
$265.10 /

-1.41 (-0.53%)

AGTC Applied Genetic
$6.39 /

+0.255 (+4.16%)

ANTM Anthem
$265.10 /

-1.41 (-0.53%)

06/05/20 Goldman Sachs
Anthem initiated with a Neutral at Goldman Sachs
06/01/20 Piper Sandler
Kentucky contract positive for Molina, negative for Anthem, says Piper Sandler
06/01/20 Stephens
Molina Healthcare price target raised to $215 from $202 at Stephens
05/21/20 SunTrust
SunTrust raises price targets across select Healthcare Services names
IMUX Immunic
$14.17 /

+0.36 (+2.61%)

06/04/20 Wedbush
Wedbush starts Immunic at Outperform with $59 price target
06/04/20 Wedbush
Immunic initiated with an Outperform at Wedbush
05/11/20
Fly Intel: Top five analyst initiations
05/11/20 H.C. Wainwright
Immunic initiated with a Buy, $45 price target at H.C. Wainwright
SRRK Scholar Rock
$19.09 /

+0.27 (+1.43%)

03/12/20
Fly Intel: Top five analyst initiations
03/11/20 Baird
Scholar Rock initiated with an Outperform at Baird
EHC Encompass Health
$63.73 /

-0.48 (-0.75%)

05/29/20 Mizuho
Encompass Health price target lowered to $87 from $90 at Mizuho
04/20/20 BMO Capital
Encompass Health price target raised to $83 from $66 at BMO Capital
03/06/20 Deutsche Bank
Encompass Health price target raised to $83 from $73 at Deutsche Bank
03/05/20 BMO Capital
Encompass Health price target raised to $95 from $88 at BMO Capital
FLXN Flexion
$12.71 /

-0.02 (-0.16%)

05/27/20 Guggenheim
Guggenheim starts coverage of four pain treatment makers with two Buys
05/26/20 Guggenheim
Flexion initiated with a Buy at Guggenheim
05/08/20 Needham
Flexion price target lowered to $20 from $30 at Needham
04/02/20 Benchmark
Flexion price target lowered to $17 from $25 at Benchmark
REGN Regeneron
$627.91 /

-15.055 (-2.34%)

06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
06/15/20 Piper Sandler
Piper says 'meaningfully above-consensus estimates' for Dupixent are right
06/12/20 Jefferies
Regeneron price target raised to $691 from $657 at Jefferies
06/02/20 Cantor Fitzgerald
Regeneron price target raised to $624 from $400 at Cantor Fitzgerald
SLGL Sol-Gel Technologies
$8.44 /

+0.2 (+2.43%)

03/26/20 H.C. Wainwright
Sol-Gel Technologies price target lowered to $21 from $26 at H.C. Wainwright
02/05/20 JMP Securities
Sol-Gel on track for two drug filings this year, says JMP Securities
12/31/19 H.C. Wainwright
Sol-Gel Technologies price target raised to $26 from $23 at H.C. Wainwright
12/31/19 BMO Capital
Sol-Gel Technologies' Twyneo result has best-in-class profile, says BMO Capital
MORF Morphic Holding
$29.62 /

+2.45 (+9.02%)

07/22/19 Jefferies
Morphic Holding initiated with a Buy at Jefferies
07/22/19 Wells Fargo
Morphic Holding initiated with an Outperform at Wells Fargo
07/22/19 BMO Capital
Morphic Holding initiated with an Outperform at BMO Capital
MNK Mallinckrodt
$2.91 /

+0.355 (+13.89%)

06/17/20 Citi
Sell Mallinckrodt, buy Endo with opioid risk coming back, says Citi
05/19/20 JPMorgan
Mallinckrodt downgraded to Underweight on unclear turnaround at JPMorgan
05/19/20 JPMorgan
Mallinckrodt downgraded to Underweight from Neutral at JPMorgan
04/24/20
Fly Intel: Top five analyst initiations
ETTX Entasis Therapeutics
$2.99 /

-0.035 (-1.16%)

05/08/20 BMO Capital
Entasis Therapeutics price target lowered to $5 from $15 at BMO Capital
04/14/20 H.C. Wainwright
Entasis Therapeutics price target lowered to $5 from $18 at H.C. Wainwright
08/19/19 H.C. Wainwright
Entasis Therapeutics initiated with a Buy at H.C. Wainwright
AGTC Applied Genetic
$6.39 /

+0.255 (+4.16%)

06/23/20 Cantor Fitzgerald
Applied Genetic initiated with an Overweight at Cantor Fitzgerald
06/22/20 Cantor Fitzgerald
Applied Genetic initiated with an Overweight at Cantor Fitzgerald
02/12/20 Roth Capital
Applied Genetic in position to execute after cash raise, says Roth Capital
01/28/20
Fly Intel: Top five analyst initiations
HZNP Horizon Therapeutics
$52.52 /

+2.545 (+5.09%)

06/10/20 Mizuho
Mizuho doctor survey shows preference for SEL-212 over Krystexxa
05/29/20 Stifel
Horizon Therapeutics price target raised to $60 from $50 at Stifel
05/21/20 Piper Sandler
Horizon Therapeutics price target raised to $61 from $50 at Piper Sandler
05/08/20 Morgan Stanley
Horizon Therapeutics price target raised to $50 from $39 at Morgan Stanley
BBIO BridgeBio
$33.07 /

+1.06 (+3.31%)

06/05/20 Mizuho
HFA slide 'good' for BridgeBio, Eidos' AG10, says Mizuho
05/29/20 Piper Sandler
Piper Sandler 'encouraged' by BridgeBio data presented at ASCO
05/19/20 BTIG
BridgeBio initiated with a Buy at BTIG
05/11/20 Piper Sandler
Piper Sandler says BridgeBio's Infigratinib 'attractive candidate' for ACH
AQST Aquestive Therapeutics
$5.42 /

+0.01 (+0.18%)

05/22/20 H.C. Wainwright
Aquestive Therapeutics price target raised to $15 from $13 at H.C. Wainwright
03/16/20 Wedbush
Aquestive Therapeutics price target lowered to $31 from $36 at Wedbush
02/10/20 Wedbush
Wedbush delays launch estimates for Libervant, ups Aquestive Therapeutics target
02/10/20 Wedbush
Aquestive price target raised to $36 at Wedbush after FDA accepts NDA
BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

06/05/20 Guggenheim
Guggenheim starts BioXcel Therapeutics at Buy on optimistic view of lead asset
06/04/20 Guggenheim
BioXcel Therapeutics initiated with a Buy at Guggenheim
04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
BioXcel Therapeutics initiated with a Buy at BofA
CNC Centene
$63.09 /

-1.08 (-1.68%)

04/29/20 Oppenheimer
Centene price target raised to $90 from $83 at Oppenheimer
04/29/20 Piper Sandler
Centene selloff yesterday a buying opportunity, says Piper Sandler
04/09/20 Jefferies
Anthem downgraded to Hold on Commercial Risk at Jefferies
LNTH Lantheus
$13.99 /

-0.58 (-3.98%)

06/16/20 CJS Securities
Lantheus upgraded to Outperform from Market Perform at CJS Securities
10/02/19 Credit Suisse
Lantheus deal for Progenics has 'some strategic merit,' says Credit Suisse
08/16/19
Lantheus upgraded to Outperform from Market Perform at CJS Securities
SDGR Schrodinger
$75.65 /

+0.49 (+0.65%)

06/02/20 BMO Capital
Schrodinger price target raised to $85 from $67 at BMO Capital
03/02/20
Fly Intel: Top five analyst initiations
03/02/20 Jefferies
Schrodinger initiated with a Hold at Jefferies
03/02/20 Morgan Stanley
Schrodinger initiated with an Equal Weight at Morgan Stanley
SCPH scPharmaceuticals
$7.55 /

+0.35 (+4.86%)

05/13/20 SVB Leerink
scPharmaceuticals price target raised to $12 from $7 at SVB Leerink
05/13/20 H.C. Wainwright
scPharmaceuticals price target raised to $15 from $13 at H.C. Wainwright
10/15/19 H.C. Wainwright
scPharmaceuticals initiated with a Buy at H.C. Wainwright
PHAT Phathom Pharmaceuticals
$45.36 /

-0.635 (-1.38%)

11/19/19 Evercore ISI
Phathom Pharmaceuticals initiated with an Outperform at Evercore ISI
11/19/19
Fly Intel: Top five analyst initiations
11/19/19 Needham
Phathom Pharmaceuticals initiated with a Buy at Needham
11/19/19 Jefferies
Phathom Pharmaceuticals initiated with a Buy at Jefferies
HUM Humana
$379.31 /

-1.3 (-0.34%)

06/18/20 Deutsche Bank
Humana price target lowered to $397 from $421 at Deutsche Bank
06/17/20 Cantor Fitzgerald
Humana price target raised to $410 from $405 at Cantor Fitzgerald
06/16/20 Cowen
Humana downgraded to Market Perform on valuation at Cowen
06/16/20 Cowen
Humana downgraded to Market Perform from Outperform at Cowen
HARP Harpoon Therapeutics
$18.18 /

-0.02 (-0.11%)

06/01/20 Wedbush
Harpoon Therapeutics price target raised to $36 from $26 at Wedbush
06/01/20 Piper Sandler
Harpoon initial data for HPN424 'highly encouraging,' says Piper Sandler
05/29/20 Roth Capital
Harpoon Therapeutics price target raised to $31 from $25 at Roth Capital
05/22/20 Piper Sandler
Harpoon Therapeutics initiated with an Overweight at Piper Sandler
SRRK Scholar Rock
$19.09 /

+0.27 (+1.43%)

SLGL Sol-Gel Technologies
$8.44 /

+0.2 (+2.43%)

SDGR Schrodinger
$75.65 /

+0.49 (+0.65%)

SCPH scPharmaceuticals
$7.55 /

+0.35 (+4.86%)

REGN Regeneron
$627.91 /

-15.055 (-2.34%)

PHAT Phathom Pharmaceuticals
$45.36 /

-0.635 (-1.38%)

MNK Mallinckrodt
$2.91 /

+0.355 (+13.89%)

LNTH Lantheus
$13.99 /

-0.58 (-3.98%)

IMUX Immunic
$14.17 /

+0.36 (+2.61%)

HZNP Horizon Therapeutics
$52.52 /

+2.545 (+5.09%)

HUM Humana
$379.31 /

-1.3 (-0.34%)

HARP Harpoon Therapeutics
$18.18 /

-0.02 (-0.11%)

FLXN Flexion
$12.71 /

-0.02 (-0.16%)

EHC Encompass Health
$63.73 /

-0.48 (-0.75%)

CNC Centene
$63.09 /

-1.08 (-1.68%)

BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

BBIO BridgeBio
$33.07 /

+1.06 (+3.31%)

AQST Aquestive Therapeutics
$5.42 /

+0.01 (+0.18%)

ANTM Anthem
$265.10 /

-1.41 (-0.53%)

AGTC Applied Genetic
$6.39 /

+0.255 (+4.16%)

SDGR Schrodinger
$75.65 /

+0.49 (+0.65%)

REGN Regeneron
$627.91 /

-15.055 (-2.34%)

MNK Mallinckrodt
$2.91 /

+0.355 (+13.89%)

HUM Humana
$379.31 /

-1.3 (-0.34%)

ANTM Anthem
$265.10 /

-1.41 (-0.53%)

SDGR Schrodinger
$75.65 /

+0.49 (+0.65%)

REGN Regeneron
$627.91 /

-15.055 (-2.34%)

MNK Mallinckrodt
$2.91 /

+0.355 (+13.89%)

IMUX Immunic
$14.17 /

+0.36 (+2.61%)

HUM Humana
$379.31 /

-1.3 (-0.34%)

HARP Harpoon Therapeutics
$18.18 /

-0.02 (-0.11%)

FLXN Flexion
$12.71 /

-0.02 (-0.16%)

ETTX Entasis Therapeutics
$2.99 /

-0.035 (-1.16%)

CNC Centene
$63.09 /

-1.08 (-1.68%)

BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

ANTM Anthem
$265.10 /

-1.41 (-0.53%)

SDGR Schrodinger
$75.65 /

+0.49 (+0.65%)

REGN Regeneron
$627.91 /

-15.055 (-2.34%)

MNK Mallinckrodt
$2.91 /

+0.355 (+13.89%)

HUM Humana
$379.31 /

-1.3 (-0.34%)

HARP Harpoon Therapeutics
$18.18 /

-0.02 (-0.11%)

CNC Centene
$63.09 /

-1.08 (-1.68%)

BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

BBIO BridgeBio
$33.07 /

+1.06 (+3.31%)

AQST Aquestive Therapeutics
$5.42 /

+0.01 (+0.18%)

ANTM Anthem
$265.10 /

-1.41 (-0.53%)

Over a quarter ago
Hot Stocks
Morphic Therapeutic appoints Marc Schegerin as CFO, COO » 08:24
04/07/20
04/07
08:24
04/07/20
08:24
MORF

Morphic Holding

$15.07 /

+1.54 (+11.38%)

Morphic Therapeutic…

Morphic Therapeutic announced the appointment of Marc Schegerin, M.D., as CFO and COO. Before joining Morphic, Dr. Schegerin served as CFO, treasurer and head of strategy & communications at ArQule.

ShowHide Related Items >><<
MORF Morphic Holding
$15.07 /

+1.54 (+11.38%)

07/22/19 Jefferies
Morphic Holding initiated with a Buy at Jefferies
07/22/19 Wells Fargo
Morphic Holding initiated with an Outperform at Wells Fargo
07/22/19 BMO Capital
Morphic Holding initiated with an Outperform at BMO Capital
Hot Stocks
Morphic Therapeutic appoints Peter Linde as CMO » 08:08
03/17/20
03/17
08:08
03/17/20
08:08
MORF

Morphic Holding

$10.68 /

-1.92 (-15.24%)

, XLRN

Acceleron

$72.89 /

-8.715 (-10.68%)

Morphic Therapeutic…

Morphic Therapeutic (MORF) announced the appointment of Peter Linde, M.D., as chief medical officer. Dr. Linde was previously vice president of medical research at Acceleron Pharma (XLRN), where he was responsible for the design and execution of clinical trials with positive outcomes in both pulmonary and hematologic diseases. Dr. Linde will oversee the development of Morphic's small molecule integrin inhibitors as the company advances its oral integrin inhibitors toward clinical trials.

ShowHide Related Items >><<
MORF Morphic Holding
$10.68 /

-1.92 (-15.24%)

07/22/19 Jefferies
Morphic Holding initiated with a Buy at Jefferies
07/22/19 Wells Fargo
Morphic Holding initiated with an Outperform at Wells Fargo
07/22/19 BMO Capital
Morphic Holding initiated with an Outperform at BMO Capital
XLRN Acceleron
$72.89 /

-8.715 (-10.68%)

02/27/20 Piper Sandler
Piper Sandler says Acceleron remains top pick
02/27/20 Barclays
Acceleron initiated with an Overweight at Barclays
02/18/20 H.C. Wainwright
Acceleron price target raised to $129 from $90 at H.C. Wainwright
02/03/20 Morgan Stanley
Morgan Stanley sees substantial upside for Acceleron in PAH
Hot Stocks
Morphic Holding Inc trading resumes  09:49
03/09/20
03/09
09:49
03/09/20
09:49
MORF

Morphic Holding

$17.26 /

+ (+0.00%)

 
ShowHide Related Items >><<
MORF Morphic Holding
$17.26 /

+ (+0.00%)

07/22/19 Jefferies
Morphic Holding initiated with a Buy at Jefferies
07/22/19 Wells Fargo
Morphic Holding initiated with an Outperform at Wells Fargo
07/22/19 BMO Capital
Morphic Holding initiated with an Outperform at BMO Capital
Hot Stocks
Morphic Holding Inc trading halted, volatility trading pause  09:32
03/09/20
03/09
09:32
03/09/20
09:32
MORF

Morphic Holding

$17.26 /

-0.44 (-2.49%)

 
ShowHide Related Items >><<
MORF Morphic Holding
$17.26 /

-0.44 (-2.49%)

07/22/19 Jefferies
Morphic Holding initiated with a Buy at Jefferies
07/22/19 Wells Fargo
Morphic Holding initiated with an Outperform at Wells Fargo
07/22/19 BMO Capital
Morphic Holding initiated with an Outperform at BMO Capital
Conference/Events
Cowen to hold a conference » 04:55
03/04/20
03/04
04:55
03/04/20
04:55
A

Agilent

$80.44 /

-1.54 (-1.88%)

, ABBV

AbbVie

$87.57 /

-1.03 (-1.16%)

, ADRO

Aduro Biotech

$3.04 /

+ (+0.00%)

, ALXN

Alexion

$93.85 /

-2.08 (-2.17%)

, BBIO

BridgeBio

$32.37 /

+0.17 (+0.53%)

, CTMX

CytomX Therapeutics

$7.28 /

+0.18 (+2.54%)

, EPZM

Epizyme

$20.71 /

-2.33 (-10.11%)

, FOMX

Foamix

$3.35 /

-0.095 (-2.76%)

, IMGN

ImmunoGen

$4.39 /

-0.02 (-0.45%)

, LLY

Eli Lilly

$130.32 /

-2.24 (-1.69%)

, MORF

Morphic Holding

$15.78 /

-0.18 (-1.13%)

, MSON

Misonix

$13.87 /

+0.01 (+0.07%)

, JNJ

Johnson & Johnson

$135.71 /

-4.28 (-3.06%)

, HZNP

Horizon Therapeutics

$34.39 /

-0.72 (-2.05%)

, GILD

Gilead

$74.26 /

-1.14 (-1.51%)

, EW

Edwards Lifesciences

$209.03 /

-3.4 (-1.60%)

, DVAX

Dynavax

$4.25 /

-0.23 (-5.13%)

, BSX

Boston Scientific

$37.22 /

-1.01 (-2.64%)

, BMRN

BioMarin

$92.66 /

-1.81 (-1.92%)

, BLUE

Bluebird Bio

$71.14 /

-2.75 (-3.72%)

, BIIB

Biogen

$315.79 /

-12.18 (-3.71%)

, CERS

Cerus

$5.02 /

-0.08 (-1.57%)

, HARP

Harpoon Therapeutics

$15.70 /

-0.56 (-3.44%)

, IRWD

Ironwood

$12.24 /

-0.44 (-3.47%)

, JAZZ

Jazz Pharmaceuticals

$115.32 /

-9.64 (-7.71%)

, MRNA

Moderna

$27.91 /

-1.965 (-6.58%)

, ZTS

Zoetis

$137.33 /

-1.56 (-1.12%)

, XOMA

Xoma

$24.48 /

-0.52 (-2.08%)

, TECH

Bio-Techne

$193.46 /

-3.94 (-2.00%)

, TMO

Thermo Fisher

$310.46 /

+5.76 (+1.89%)

, SEEL

Seelos Therapeutics

$0.87 /

-0.0238 (-2.67%)

, PIRS

Pieris Pharmaceuticals

$3.16 /

-0.13 (-3.95%)

, PFE

Pfizer

$34.27 /

-0.62 (-1.78%)

, PBYI

Puma Biotechnology

$10.42 /

-0.25 (-2.34%)

, NLTX

Neoleukin Therapeutics

$10.59 /

-0.03 (-0.28%)

, OXFD

Oxford Immunotec

$13.21 /

-0.1 (-0.75%)

, RYTM

Rhythm Pharmaceuticals

$19.59 /

-0.83 (-4.06%)

40th Annual Healthcare…

40th Annual Healthcare Conference will be held in Boston on March 2-4.

ShowHide Related Items >><<
A Agilent
$80.44 /

-1.54 (-1.88%)

02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/19/20 Piper Sandler
Agilent price target raised to $96 from $86 at Piper Sandler
02/06/20 Cowen
Developments in Agilent-Twist dispute could mean settlement imminent, says Cowen
ABBV AbbVie
$87.57 /

-1.03 (-1.16%)

02/27/20 Barclays
AbbVie initiated with an Equal Weight at Barclays
02/18/20 Cowen
AbbVie price target raised to $105 from $98 at Cowen
02/14/20 Piper Sandler
Piper says Ubrelvy prescription trajectory bodes well for Biohaven's rimegepant
02/11/20 SunTrust
Allergan price target raised to $202 from $194 at SunTrust
ADRO Aduro Biotech
$3.04 /

+ (+0.00%)

01/10/20 Cowen
Aduro downgraded to Market Perform on limited visibility at Cowen
01/10/20 Cowen
Aduro Biotech downgraded to Market Perform from Outperform at Cowen
12/18/19 H.C. Wainwright
Aduro Biotech price target lowered to $4 from $7 at H.C. Wainwright
12/18/19 William Blair
Aduro Biotech downgraded to Market Perform from Outperform at William Blair
ALXN Alexion
$93.85 /

-2.08 (-2.17%)

02/25/20 Citi
Alexion loses catalyst with removal of ABY-039, says Citi
02/03/20 Nomura Instinet
Alexion price target lowered to $133 from $165 at Nomura Instinet
01/31/20 Baird
Alexion price target lowered to $140 from $165 at Baird
01/31/20 RBC Capital
Alexion reinstated with Outperform rating after Achillion acquisition
BBIO BridgeBio
$32.37 /

+0.17 (+0.53%)

02/19/20
Fly Intel: Top five analyst initiations
02/19/20 Mizuho
Mizuho starts BridgeBio with Buy rating, $51 price target
02/18/20 Mizuho
BridgeBio initiated with a Buy at Mizuho
01/07/20 Raymond James
BridgeBio price target raised to $40 from $36 at Raymond James
CTMX CytomX Therapeutics
$7.28 /

+0.18 (+2.54%)

02/27/20 Piper Sandler
CytomX Therapeutics heading for platform validation, says Piper Sandler
02/24/20 H.C. Wainwright
CytomX partner's Phase 2 initiation triggers milestone, says H.C. Wainwright
11/20/19 Guggenheim
Guggenheim starts CytomX Therapeutics with Buy rating, $16 price target
11/19/19 Guggenheim
CytomX Therapeutics initiated with a Buy at Guggenheim
EPZM Epizyme
$20.71 /

-2.33 (-10.11%)

02/25/20 H.C. Wainwright
Epizyme price target raised to $36 from $25 at H.C. Wainwright
02/24/20 Jefferies
Epizyme, Blueprint among cancer companies that fit M&A criteria, says Jefferies
01/24/20 Cowen
Epizyme price target raised to $36 from $18 at Cowen
01/24/20 SVB Leerink
SVB Leerink moving to the sidelines on Epizyme after Tazverik approval
FOMX Foamix
$3.35 /

-0.095 (-2.76%)

10/21/19 H.C. Wainwright
Foamix price target raised to $11 from $10 at H.C. Wainwright
10/16/19 Barclays
Barclays likes Foamix setup into October 20 FDA action date
10/08/19 Cantor Fitzgerald
Cantor reiterates Overweight on Foamix ahead of FMX101 PDUFA
06/11/19 Barclays
Foamix initiated with an Overweight at Barclays
IMGN ImmunoGen
$4.39 /

-0.02 (-0.45%)

12/17/19 H.C. Wainwright
ImmunoGen price target hiked to $9 after 'compelling' advance at H.C. Wainwright
09/29/19 Piper Sandler
Biomarker screening reason for ImmunoGen FORWARD I failure, says Piper Jaffray
05/15/19 H.C. Wainwright
H.C. Wainwright says 'wrong again' about ImmunoGen, lowers price target to $4
05/15/19 Guggenheim
ImmunoGen downgraded to Neutral from Buy at Guggenheim
LLY Eli Lilly
$130.32 /

-2.24 (-1.69%)

02/27/20 Barclays
Eli Lilly initiated with an Overweight at Barclays
02/18/20 Piper Sandler
Xeris Pharmaceuticals initiated with an Overweight at Piper Sandler
02/10/20 William Blair
William Blair sees little change to sentiment for aducanumab after DIAN-TU fails
02/05/20 Mizuho
Eli Lilly initiated with a Neutral at Mizuho
MORF Morphic Holding
$15.78 /

-0.18 (-1.13%)

07/22/19 Jefferies
Morphic Holding initiated with a Buy at Jefferies
07/22/19 Wells Fargo
Morphic Holding initiated with an Outperform at Wells Fargo
07/22/19 BMO Capital
Morphic Holding initiated with an Outperform at BMO Capital
MSON Misonix
$13.87 /

+0.01 (+0.07%)

12/31/19 Craig-Hallum
Misonix's amended credit line removes capital needs questions, says Craig-Hallum
08/15/19 Canaccord
Misonix price target raised to $30 from $24 at Canaccord
06/12/19
Fly Intel: Top five analyst initiations
06/12/19 BTIG
Misonix initiated with a Buy at BTIG
JNJ Johnson & Johnson
$135.71 /

-4.28 (-3.06%)

03/02/20 Wells Fargo
Baxter, J&J best positioned to weather coronavirus spread, says Wells Fargo
01/27/20 Credit Suisse
Johnson & Johnson price target raised to $170 from $163 at Credit Suisse
01/21/20 SVB Leerink
SVB Leerink bearish on Arrowhead, initiates with an Underperform
01/10/20 BWS Financial
Anika acquisitions set up direct competition with partner, says BWS Financial
HZNP Horizon Therapeutics
$34.39 /

-0.72 (-2.05%)

02/21/20 Cantor Fitzgerald
Selecta positioned for 50%-100% rally on positive data, says Cantor Fitzgerald
01/22/20 BMO Capital
Horizon Therapeutics price target raised to $46 from $40 at BMO Capita
01/22/20 Guggenheim
Horizon's label for Tepezza 'broad and incredibly clean,' says Guggenheim
01/14/20 JMP Securities
Horizon Therapeutics price target raised to $47 from $38 at JMP Securities
GILD Gilead
$74.26 /

-1.14 (-1.51%)

03/03/20 Canaccord
Forty Seven downgraded to Hold from Buy at Canaccord
03/02/20 H.C. Wainwright
Forty Seven downgraded to Neutral from Buy at H.C. Wainwright
03/02/20 Roth Capital
Forty Seven downgraded to Neutral from Buy at Roth Capital
02/28/20 Benchmark
Ligand a 'coronavirus play in the making,' says Benchmark
EW Edwards Lifesciences
$209.03 /

-3.4 (-1.60%)

02/12/20 Goldman Sachs
Edwards Lifesciences initiated with a Neutral at Goldman Sachs
01/31/20 Piper Sandler
Edwards Lifesciences price target raised to $270 from $262 at Piper Sandler
01/10/20 Wells Fargo
Wells says PTAB ruling of 'zero importance' to bigger Abbott-Edwards fight
01/10/20
Fly Intel: Top five analyst upgrades
DVAX Dynavax
$4.25 /

-0.23 (-5.13%)

10/18/19 H.C. Wainwright
Dynavax initiated with a Buy at H.C. Wainwright
07/10/19 Cantor Fitzgerald
Dynavax upgraded to Overweight from Neutral at Cantor Fitzgerald
06/18/19 BMO Capital
VBI Vaccines price target lowered to $5 from $12 at BMO Capital
05/24/19 RBC Capital
Dynavax price target lowered to $13 from $19 at RBC Capital
BSX Boston Scientific
$37.22 /

-1.01 (-2.64%)

03/03/20 Piper Sandler
Piper recommends three Med Tech names amid coronavirus selloff
02/12/20 Goldman Sachs
Boston Scientific initiated with a Neutral at Goldman Sachs
02/05/20 Piper Sandler
Piper Sandler constructive on Boston Scientific given guidance, new product flow
01/17/20 Piper Sandler
FDA recommendation a 'solid tailwind' for Boston Scientific, says Piper Sandler
BMRN BioMarin
$92.66 /

-1.81 (-1.92%)

03/02/20 Wedbush
BioMarin price target lowered to $164 from $175 at Wedbush
02/28/20 Citi
BioMarin price target raised to $105 from $95 at Citi
02/27/20 Oppenheimer
BioMarin price target raised to $88 from $80 at Oppenheimer
02/26/20 Piper Sandler
BioMarin firing on all cylinders, says Piper Sandler
BLUE Bluebird Bio
$71.14 /

-2.75 (-3.72%)

02/20/20 Oppenheimer
Bluebird Bio price target lowered to $128 from $135 at Oppenheimer
02/19/20 Raymond James
Bluebird Bio downgraded to Market Perform from Strong Buy at Raymond James
02/19/20 Piper Sandler
Bluebird pushed Biologics License Application to second half, says Piper Sandler
02/03/20 Evercore ISI
Bluebird Bio upgraded to Outperform on undervalued assets at Evercore ISI
BIIB Biogen
$315.79 /

-12.18 (-3.71%)

02/28/20 William Blair
Biogen deal with Sangamo unlikely to have near-term impact, says William Blair
02/27/20 Barclays
Biogen initiated with an Overweight at Barclays
02/24/20 Jefferies
Jefferies starts Denali Therapeutics at Buy ahead of 'lots of catalysts in 2020'
CERS Cerus
$5.02 /

-0.08 (-1.57%)

02/26/20 BTIG
Cerus initiated with a Buy at BTIG
01/23/20 Cowen
Cowen encouraged by Cerus data on Intercept in light of new coronavirus
11/13/19 BTIG
Cerus upgraded to Buy from Neutral at BTIG
08/28/19
Fly Intel: Top five analyst initiations
HARP Harpoon Therapeutics
$15.70 /

-0.56 (-3.44%)

02/28/20
Fly Intel: Top five analyst initiations
02/27/20 SunTrust
Harpoon Therapeutics initiated with a Buy at SunTrust
02/03/20
Fly Intel: Top five analyst initiations
02/03/20 H.C. Wainwright
Harpoon Therapeutics initiated with a Buy at H.C. Wainwright
IRWD Ironwood
$12.24 /

-0.44 (-3.47%)

08/05/19 Credit Suisse
Ironwood assumed with a Neutral at Credit Suisse
07/10/19 Credit Suisse
Ironwood assumed with a Neutral at Credit Suisse
03/27/19 Morgan Stanley
Morgan Stanley upgrades Ironwood to Equal Weight on more stable Linzess growth
03/27/19 Morgan Stanley
Ironwood upgraded to Equal Weight from Underweight at Morgan Stanley
JAZZ Jazz Pharmaceuticals
$115.32 /

-9.64 (-7.71%)

02/26/20 RBC Capital
Jazz Pharmaceuticals price target lowered to $164 from $184 at RBC Capital
02/26/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $154 from $183 at Oppenheimer
02/26/20 Cowen
Jazz Pharmaceuticals lowered his price target to $165 from $200 at Cowen
02/26/20 Piper Sandler
Jazz Pharmaceuticals price target lowered to $129 from $142 at Piper Sandler
MRNA Moderna
$27.91 /

-1.965 (-6.58%)

02/28/20 Piper Sandler
Moderna has five potential mRNA rare disease blockbusters, says Piper Sandler
02/27/20 JPMorgan
Moderna price target raised to $32 from $24 at JPMorgan
02/27/20 Roth Capital
Moderna price target raised to $33 from $24 at Roth Capital
02/26/20 Piper Sandler
Piper Sandler backs rating on Moderna after coronavirus vaccine shipped
ZTS Zoetis
$137.33 /

-1.56 (-1.12%)

02/14/20 SunTrust
Zoetis price target raised to $145 from $130 at SunTrust
01/10/20 Raymond James
Zoetis' premium valuation vs. peers likely to persist, says Raymond James
01/09/20 Raymond James
Zoetis initiated with a Market Perform at Raymond James
12/19/19 BofA
Elanco upgraded to Buy from Neutral at BofA/Merrill
XOMA Xoma
$24.48 /

-0.52 (-2.08%)

TECH Bio-Techne
$193.46 /

-3.94 (-2.00%)

02/24/20 Eight Capital
Bio-Techne downgraded to Neutral from Buy at Eight Capital
01/08/20 Stephens
Bio-Techne resumed with an Overweight at Stephens
01/07/20 Wells Fargo
Bio-Techne initiated with an Equal Weight at Wells Fargo
01/06/20 Citi
Bio-Techne initiated with a Neutral at Citi
TMO Thermo Fisher
$310.46 /

+5.76 (+1.89%)

03/04/20 Berenberg
Qiagen downgraded to Hold from Buy at Berenberg
03/03/20 Piper Sandler
Danaher unlikely to make competing bid for Qiagen, says Piper Sandler
02/24/20 Argus
Thermo Fisher price target raised to $370 from $340 at Argus
01/31/20 BTIG
Thermo Fisher price target raised to $372 from $342 at BTIG
SEEL Seelos Therapeutics
$0.87 /

-0.0238 (-2.67%)

11/18/19 H.C. Wainwright
Seelos Therapeutics price target lowered to $2 from $4 at H.C. Wainwright
11/14/19 Benchmark
Seelos Therapeutics initiated with a Speculative Buy at Benchmark
05/14/19 Roth Capital
Seelos Therapeutics initiated with a Buy at Roth Capital
05/10/19 H.C. Wainwright
Seelos Therapeutics initiated with a Buy at H.C. Wainwright
PIRS Pieris Pharmaceuticals
$3.16 /

-0.13 (-3.95%)

01/27/20 H.C. Wainwright
Pieris Pharmaceuticals price target raised to $9 from $7 at H.C. Wainwright
07/30/19 Baird
Pieris Pharmaceuticals downgraded to Neutral from Outperform at Baird
07/29/19 William Blair
Updates 'very positive' for upcoming Pieris presentation, says William Blair
05/14/19 Baird
Pieris Pharmaceuticals initiated with an Outperform at Baird
PFE Pfizer
$34.27 /

-0.62 (-1.78%)

02/27/20 Standpoint Research
Pfizer upgraded to Buy from Hold at Standpoint Research
02/27/20 Barclays
Pfizer initiated with an Equal Weight at Barclays
02/12/20 Baird
Exact Sciences weakness would be buying opportunity, says Baird
02/11/20 Roth Capital
GlycoMimetics termination notice from Pfizer no surprise, says Roth Capital
PBYI Puma Biotechnology
$10.42 /

-0.25 (-2.34%)

12/06/19 H.C. Wainwright
Puma Biotechnology initiated with a Buy at H.C. Wainwright
11/08/19 Cantor Fitzgerald
Puma Biotechnology price target lowered to $14 from $20 at Cantor Fitzgerald
11/07/19 RBC Capital
Puma Biotechnology price target lowered to $13 from $23 at RBC Capital
11/07/19 Barclays
Puma Biotechnology price target lowered to $6 from $9 at Barclays
NLTX Neoleukin Therapeutics
$10.59 /

-0.03 (-0.28%)

02/18/20
Fly Intel: Top five analyst initiations
02/18/20 Guggenheim
Guggenheim starts Neoleukin Therapeutics at Buy with $20 price target
02/18/20 Guggenheim
Neoleukin Therapeutics initiated with a Buy at Guggenheim
01/10/20 Piper Sandler
Neoleukin Therapeutics initiated with an Overweight at Piper Sandler
OXFD Oxford Immunotec
$13.21 /

-0.1 (-0.75%)

09/24/19 Cowen
Oxford Immunotec company sale may make sense, says Cowen
09/18/19 Piper Sandler
Oxford Immunotec's new approach to China could boost sales, says Piper Jaffray
03/12/19 Baird
Oxford Immunotec's 2019 guidance seems 'conservative,' says Baird
03/12/19 Piper Sandler
Oxford Immunotec well positioned for strong 2019 transition, says Piper Jaffray
RYTM Rhythm Pharmaceuticals
$19.59 /

-0.83 (-4.06%)

01/08/20 Goldman Sachs
Rhythm Pharmaceuticals initiated with a Sell at Goldman Sachs
07/12/19 Stifel
Rhythm Pharmaceuticals upgraded to Buy from Hold at Stifel
03/13/19
Fly Intel: Top five analyst initiations
03/13/19 Ladenburg
Ladenburg starts Rhythm Pharmaceuticals with Buy rating, $43 price target
Conference/Events
Cowen to hold a conference » 04:55
03/03/20
03/03
04:55
03/03/20
04:55
A

Agilent

$81.98 /

+4.4 (+5.67%)

, ABBV

AbbVie

$88.60 /

+3.265 (+3.83%)

, ADRO

Aduro Biotech

$3.04 /

+0.09 (+3.05%)

, ALXN

Alexion

$95.93 /

+3.8 (+4.12%)

, BBIO

BridgeBio

$32.20 /

+1.71 (+5.61%)

, CTMX

CytomX Therapeutics

$7.10 /

-0.02 (-0.28%)

, EPZM

Epizyme

$23.04 /

+2.57 (+12.55%)

, FOMX

Foamix

$3.45 /

-0.09 (-2.55%)

, IMGN

ImmunoGen

$4.41 /

+0.02 (+0.46%)

, LLY

Eli Lilly

$132.56 /

+6.1 (+4.82%)

, MORF

Morphic Holding

$15.96 /

+0.28 (+1.79%)

, MSON

Misonix

$13.86 /

-0.48 (-3.35%)

, JNJ

Johnson & Johnson

$139.99 /

+1.03 (+0.74%)

, HZNP

Horizon Therapeutics

$35.11 /

+1.08 (+3.17%)

, GILD

Gilead

$75.40 /

+2.74 (+3.77%)

, EW

Edwards Lifesciences

$212.43 /

-0.63 (-0.30%)

, DVAX

Dynavax

$4.48 /

+0.52 (+13.13%)

, BSX

Boston Scientific

$38.23 /

+0.34 (+0.90%)

, BMRN

BioMarin

$94.47 /

+4.61 (+5.13%)

, BLUE

Bluebird Bio

$73.89 /

+6.79 (+10.12%)

, BIIB

Biogen

$327.97 /

+18.1 (+5.84%)

, CERS

Cerus

$5.10 /

-0.07 (-1.35%)

, HARP

Harpoon Therapeutics

$16.26 /

+2.01 (+14.11%)

, IRWD

Ironwood

$12.68 /

+0.775 (+6.51%)

, JAZZ

Jazz Pharmaceuticals

$124.96 /

+11.835 (+10.46%)

, MRNA

Moderna

$29.87 /

+3.71 (+14.18%)

, ZTS

Zoetis

$138.89 /

+4.94 (+3.69%)

, XOMA

Xoma

$25.00 /

+1.32 (+5.57%)

, TECH

Bio-Techne

$197.40 /

+3.82 (+1.97%)

, TMO

Thermo Fisher

$304.70 /

+6.54 (+2.19%)

, SEEL

Seelos Therapeutics

$0.89 /

+0.05 (+5.95%)

, PIRS

Pieris Pharmaceuticals

$3.29 /

+0.15 (+4.78%)

, PFE

Pfizer

$34.89 /

+0.77 (+2.26%)

, PBYI

Puma Biotechnology

$10.67 /

+0.65 (+6.49%)

, NLTX

Neoleukin Therapeutics

$10.62 /

+0.47 (+4.63%)

, OXFD

Oxford Immunotec

$13.31 /

-0.19 (-1.41%)

, RYTM

Rhythm Pharmaceuticals

$20.42 /

+2.27 (+12.51%)

40th Annual Healthcare…

40th Annual Healthcare Conference will be held in Boston on March 2-4.

ShowHide Related Items >><<
A Agilent
$81.98 /

+4.4 (+5.67%)

02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/19/20 Piper Sandler
Agilent price target raised to $96 from $86 at Piper Sandler
02/06/20 Cowen
Developments in Agilent-Twist dispute could mean settlement imminent, says Cowen
ABBV AbbVie
$88.60 /

+3.265 (+3.83%)

02/27/20 Barclays
AbbVie initiated with an Equal Weight at Barclays
02/18/20 Cowen
AbbVie price target raised to $105 from $98 at Cowen
02/14/20 Piper Sandler
Piper says Ubrelvy prescription trajectory bodes well for Biohaven's rimegepant
02/11/20 SunTrust
Allergan price target raised to $202 from $194 at SunTrust
ADRO Aduro Biotech
$3.04 /

+0.09 (+3.05%)

01/10/20 Cowen
Aduro downgraded to Market Perform on limited visibility at Cowen
01/10/20 Cowen
Aduro Biotech downgraded to Market Perform from Outperform at Cowen
12/18/19 H.C. Wainwright
Aduro Biotech price target lowered to $4 from $7 at H.C. Wainwright
12/18/19 William Blair
Aduro Biotech downgraded to Market Perform from Outperform at William Blair
ALXN Alexion
$95.93 /

+3.8 (+4.12%)

02/25/20 Citi
Alexion loses catalyst with removal of ABY-039, says Citi
02/03/20 Nomura Instinet
Alexion price target lowered to $133 from $165 at Nomura Instinet
01/31/20 Baird
Alexion price target lowered to $140 from $165 at Baird
01/31/20 RBC Capital
Alexion reinstated with Outperform rating after Achillion acquisition
BBIO BridgeBio
$32.20 /

+1.71 (+5.61%)

02/19/20
Fly Intel: Top five analyst initiations
02/19/20 Mizuho
Mizuho starts BridgeBio with Buy rating, $51 price target
02/18/20 Mizuho
BridgeBio initiated with a Buy at Mizuho
01/07/20 Raymond James
BridgeBio price target raised to $40 from $36 at Raymond James
CTMX CytomX Therapeutics
$7.10 /

-0.02 (-0.28%)

02/27/20 Piper Sandler
CytomX Therapeutics heading for platform validation, says Piper Sandler
02/24/20 H.C. Wainwright
CytomX partner's Phase 2 initiation triggers milestone, says H.C. Wainwright
11/20/19 Guggenheim
Guggenheim starts CytomX Therapeutics with Buy rating, $16 price target
11/19/19 Guggenheim
CytomX Therapeutics initiated with a Buy at Guggenheim
EPZM Epizyme
$23.04 /

+2.57 (+12.55%)

02/25/20 H.C. Wainwright
Epizyme price target raised to $36 from $25 at H.C. Wainwright
02/24/20 Jefferies
Epizyme, Blueprint among cancer companies that fit M&A criteria, says Jefferies
01/24/20 Cowen
Epizyme price target raised to $36 from $18 at Cowen
01/24/20 SVB Leerink
SVB Leerink moving to the sidelines on Epizyme after Tazverik approval
FOMX Foamix
$3.45 /

-0.09 (-2.55%)

10/21/19 H.C. Wainwright
Foamix price target raised to $11 from $10 at H.C. Wainwright
10/16/19 Barclays
Barclays likes Foamix setup into October 20 FDA action date
10/08/19 Cantor Fitzgerald
Cantor reiterates Overweight on Foamix ahead of FMX101 PDUFA
06/11/19 Barclays
Foamix initiated with an Overweight at Barclays
IMGN ImmunoGen
$4.41 /

+0.02 (+0.46%)

12/17/19 H.C. Wainwright
ImmunoGen price target hiked to $9 after 'compelling' advance at H.C. Wainwright
09/29/19 Piper Sandler
Biomarker screening reason for ImmunoGen FORWARD I failure, says Piper Jaffray
05/15/19 H.C. Wainwright
H.C. Wainwright says 'wrong again' about ImmunoGen, lowers price target to $4
05/15/19 Guggenheim
ImmunoGen downgraded to Neutral from Buy at Guggenheim
LLY Eli Lilly
$132.56 /

+6.1 (+4.82%)

02/27/20 Barclays
Eli Lilly initiated with an Overweight at Barclays
02/18/20 Piper Sandler
Xeris Pharmaceuticals initiated with an Overweight at Piper Sandler
02/10/20 William Blair
William Blair sees little change to sentiment for aducanumab after DIAN-TU fails
02/05/20 Mizuho
Eli Lilly initiated with a Neutral at Mizuho
MORF Morphic Holding
$15.96 /

+0.28 (+1.79%)

07/22/19 Jefferies
Morphic Holding initiated with a Buy at Jefferies
07/22/19 Wells Fargo
Morphic Holding initiated with an Outperform at Wells Fargo
07/22/19 BMO Capital
Morphic Holding initiated with an Outperform at BMO Capital
MSON Misonix
$13.86 /

-0.48 (-3.35%)

12/31/19 Craig-Hallum
Misonix's amended credit line removes capital needs questions, says Craig-Hallum
08/15/19 Canaccord
Misonix price target raised to $30 from $24 at Canaccord
06/12/19
Fly Intel: Top five analyst initiations
06/12/19 BTIG
Misonix initiated with a Buy at BTIG
JNJ Johnson & Johnson
$139.99 /

+1.03 (+0.74%)

03/02/20 Wells Fargo
Baxter, J&J best positioned to weather coronavirus spread, says Wells Fargo
01/27/20 Credit Suisse
Johnson & Johnson price target raised to $170 from $163 at Credit Suisse
01/21/20 SVB Leerink
SVB Leerink bearish on Arrowhead, initiates with an Underperform
01/10/20 BWS Financial
Anika acquisitions set up direct competition with partner, says BWS Financial
HZNP Horizon Therapeutics
$35.11 /

+1.08 (+3.17%)

02/21/20 Cantor Fitzgerald
Selecta positioned for 50%-100% rally on positive data, says Cantor Fitzgerald
01/22/20 BMO Capital
Horizon Therapeutics price target raised to $46 from $40 at BMO Capita
01/22/20 Guggenheim
Horizon's label for Tepezza 'broad and incredibly clean,' says Guggenheim
01/14/20 JMP Securities
Horizon Therapeutics price target raised to $47 from $38 at JMP Securities
GILD Gilead
$75.40 /

+2.74 (+3.77%)

03/02/20 H.C. Wainwright
Forty Seven downgraded to Neutral from Buy at H.C. Wainwright
03/02/20 Roth Capital
Forty Seven downgraded to Neutral from Buy at Roth Capital
02/28/20 Benchmark
Ligand a 'coronavirus play in the making,' says Benchmark
02/28/20 Mizuho
Over 100% oncology buyout premiums suggestive of Forty Seven deal, says Mizuho
EW Edwards Lifesciences
$212.43 /

-0.63 (-0.30%)

02/12/20 Goldman Sachs
Edwards Lifesciences initiated with a Neutral at Goldman Sachs
01/31/20 Piper Sandler
Edwards Lifesciences price target raised to $270 from $262 at Piper Sandler
01/10/20 Wells Fargo
Wells says PTAB ruling of 'zero importance' to bigger Abbott-Edwards fight
01/10/20
Fly Intel: Top five analyst upgrades
DVAX Dynavax
$4.48 /

+0.52 (+13.13%)

10/18/19 H.C. Wainwright
Dynavax initiated with a Buy at H.C. Wainwright
07/10/19 Cantor Fitzgerald
Dynavax upgraded to Overweight from Neutral at Cantor Fitzgerald
06/18/19 BMO Capital
VBI Vaccines price target lowered to $5 from $12 at BMO Capital
05/24/19 RBC Capital
Dynavax price target lowered to $13 from $19 at RBC Capital
BSX Boston Scientific
$38.23 /

+0.34 (+0.90%)

02/12/20 Goldman Sachs
Boston Scientific initiated with a Neutral at Goldman Sachs
02/05/20 Piper Sandler
Piper Sandler constructive on Boston Scientific given guidance, new product flow
01/17/20 Piper Sandler
FDA recommendation a 'solid tailwind' for Boston Scientific, says Piper Sandler
01/15/20 Cowen
Boston Scientific weakness a buying opportunity, says Cowen
BMRN BioMarin
$94.47 /

+4.61 (+5.13%)

03/02/20 Wedbush
BioMarin price target lowered to $164 from $175 at Wedbush
02/28/20 Citi
BioMarin price target raised to $105 from $95 at Citi
02/27/20 Oppenheimer
BioMarin price target raised to $88 from $80 at Oppenheimer
02/26/20 Piper Sandler
BioMarin firing on all cylinders, says Piper Sandler
BLUE Bluebird Bio
$73.89 /

+6.79 (+10.12%)

02/20/20 Oppenheimer
Bluebird Bio price target lowered to $128 from $135 at Oppenheimer
02/19/20 Raymond James
Bluebird Bio downgraded to Market Perform from Strong Buy at Raymond James
02/19/20 Piper Sandler
Bluebird pushed Biologics License Application to second half, says Piper Sandler
02/03/20 Evercore ISI
Bluebird Bio upgraded to Outperform on undervalued assets at Evercore ISI
BIIB Biogen
$327.97 /

+18.1 (+5.84%)

02/28/20 William Blair
Biogen deal with Sangamo unlikely to have near-term impact, says William Blair
02/27/20 Barclays
Biogen initiated with an Overweight at Barclays
02/24/20 Jefferies
Jefferies starts Denali Therapeutics at Buy ahead of 'lots of catalysts in 2020'
CERS Cerus
$5.10 /

-0.07 (-1.35%)

02/26/20 BTIG
Cerus initiated with a Buy at BTIG
01/23/20 Cowen
Cowen encouraged by Cerus data on Intercept in light of new coronavirus
11/13/19 BTIG
Cerus upgraded to Buy from Neutral at BTIG
08/28/19
Fly Intel: Top five analyst initiations
HARP Harpoon Therapeutics
$16.26 /

+2.01 (+14.11%)

02/28/20
Fly Intel: Top five analyst initiations
02/27/20 SunTrust
Harpoon Therapeutics initiated with a Buy at SunTrust
02/03/20
Fly Intel: Top five analyst initiations
02/03/20 H.C. Wainwright
Harpoon Therapeutics initiated with a Buy at H.C. Wainwright
IRWD Ironwood
$12.68 /

+0.775 (+6.51%)

08/05/19 Credit Suisse
Ironwood assumed with a Neutral at Credit Suisse
07/10/19 Credit Suisse
Ironwood assumed with a Neutral at Credit Suisse
03/27/19 Morgan Stanley
Morgan Stanley upgrades Ironwood to Equal Weight on more stable Linzess growth
03/27/19 Morgan Stanley
Ironwood upgraded to Equal Weight from Underweight at Morgan Stanley
JAZZ Jazz Pharmaceuticals
$124.96 /

+11.835 (+10.46%)

02/26/20 RBC Capital
Jazz Pharmaceuticals price target lowered to $164 from $184 at RBC Capital
02/26/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $154 from $183 at Oppenheimer
02/26/20 Cowen
Jazz Pharmaceuticals lowered his price target to $165 from $200 at Cowen
02/26/20 Piper Sandler
Jazz Pharmaceuticals price target lowered to $129 from $142 at Piper Sandler
MRNA Moderna
$29.87 /

+3.71 (+14.18%)

02/28/20 Piper Sandler
Moderna has five potential mRNA rare disease blockbusters, says Piper Sandler
02/27/20 JPMorgan
Moderna price target raised to $32 from $24 at JPMorgan
02/27/20 Roth Capital
Moderna price target raised to $33 from $24 at Roth Capital
02/26/20 Piper Sandler
Piper Sandler backs rating on Moderna after coronavirus vaccine shipped
ZTS Zoetis
$138.89 /

+4.94 (+3.69%)

02/14/20 SunTrust
Zoetis price target raised to $145 from $130 at SunTrust
01/10/20 Raymond James
Zoetis' premium valuation vs. peers likely to persist, says Raymond James
01/09/20 Raymond James
Zoetis initiated with a Market Perform at Raymond James
12/19/19 BofA
Elanco upgraded to Buy from Neutral at BofA/Merrill
XOMA Xoma
$25.00 /

+1.32 (+5.57%)

TECH Bio-Techne
$197.40 /

+3.82 (+1.97%)

02/24/20 Eight Capital
Bio-Techne downgraded to Neutral from Buy at Eight Capital
01/08/20 Stephens
Bio-Techne resumed with an Overweight at Stephens
01/07/20 Wells Fargo
Bio-Techne initiated with an Equal Weight at Wells Fargo
01/06/20 Citi
Bio-Techne initiated with a Neutral at Citi
TMO Thermo Fisher
$304.70 /

+6.54 (+2.19%)

02/24/20 Argus
Thermo Fisher price target raised to $370 from $340 at Argus
01/31/20 BTIG
Thermo Fisher price target raised to $372 from $342 at BTIG
01/31/20 Baird
Thermo Fisher weakness a buying opportunity, says Baird
01/31/20 Citi
Thermo Fisher earnings selloff a buying opportunity, says Citi
SEEL Seelos Therapeutics
$0.89 /

+0.05 (+5.95%)

11/18/19 H.C. Wainwright
Seelos Therapeutics price target lowered to $2 from $4 at H.C. Wainwright
11/14/19 Benchmark
Seelos Therapeutics initiated with a Speculative Buy at Benchmark
05/14/19 Roth Capital
Seelos Therapeutics initiated with a Buy at Roth Capital
05/10/19 H.C. Wainwright
Seelos Therapeutics initiated with a Buy at H.C. Wainwright
PIRS Pieris Pharmaceuticals
$3.29 /

+0.15 (+4.78%)

01/27/20 H.C. Wainwright
Pieris Pharmaceuticals price target raised to $9 from $7 at H.C. Wainwright
07/30/19 Baird
Pieris Pharmaceuticals downgraded to Neutral from Outperform at Baird
07/29/19 William Blair
Updates 'very positive' for upcoming Pieris presentation, says William Blair
05/14/19 Baird
Pieris Pharmaceuticals initiated with an Outperform at Baird
PFE Pfizer
$34.89 /

+0.77 (+2.26%)

02/27/20 Standpoint Research
Pfizer upgraded to Buy from Hold at Standpoint Research
02/27/20 Barclays
Pfizer initiated with an Equal Weight at Barclays
02/12/20 Baird
Exact Sciences weakness would be buying opportunity, says Baird
02/11/20 Roth Capital
GlycoMimetics termination notice from Pfizer no surprise, says Roth Capital
PBYI Puma Biotechnology
$10.67 /

+0.65 (+6.49%)

12/06/19 H.C. Wainwright
Puma Biotechnology initiated with a Buy at H.C. Wainwright
11/08/19 Cantor Fitzgerald
Puma Biotechnology price target lowered to $14 from $20 at Cantor Fitzgerald
11/07/19 RBC Capital
Puma Biotechnology price target lowered to $13 from $23 at RBC Capital
11/07/19 Barclays
Puma Biotechnology price target lowered to $6 from $9 at Barclays
NLTX Neoleukin Therapeutics
$10.62 /

+0.47 (+4.63%)

02/18/20
Fly Intel: Top five analyst initiations
02/18/20 Guggenheim
Guggenheim starts Neoleukin Therapeutics at Buy with $20 price target
02/18/20 Guggenheim
Neoleukin Therapeutics initiated with a Buy at Guggenheim
01/10/20 Piper Sandler
Neoleukin Therapeutics initiated with an Overweight at Piper Sandler
OXFD Oxford Immunotec
$13.31 /

-0.19 (-1.41%)

09/24/19 Cowen
Oxford Immunotec company sale may make sense, says Cowen
09/18/19 Piper Sandler
Oxford Immunotec's new approach to China could boost sales, says Piper Jaffray
03/12/19 Baird
Oxford Immunotec's 2019 guidance seems 'conservative,' says Baird
03/12/19 Piper Sandler
Oxford Immunotec well positioned for strong 2019 transition, says Piper Jaffray
RYTM Rhythm Pharmaceuticals
$20.42 /

+2.27 (+12.51%)

01/08/20 Goldman Sachs
Rhythm Pharmaceuticals initiated with a Sell at Goldman Sachs
07/12/19 Stifel
Rhythm Pharmaceuticals upgraded to Buy from Hold at Stifel
03/13/19
Fly Intel: Top five analyst initiations
03/13/19 Ladenburg
Ladenburg starts Rhythm Pharmaceuticals with Buy rating, $43 price target
Conference/Events
Cowen to hold a conference » 08:00
03/02/20
03/02
08:00
03/02/20
08:00
A

Agilent

$76.99 /

-0.59 (-0.76%)

, ABBV

AbbVie

$85.27 /

-0.065 (-0.08%)

, ADRO

Aduro Biotech

$3.06 /

+0.11 (+3.73%)

, ALXN

Alexion

$93.69 /

+1.56 (+1.69%)

, BBIO

BridgeBio

$31.75 /

+1.26 (+4.13%)

, CTMX

CytomX Therapeutics

$6.73 /

-0.39 (-5.48%)

, EPZM

Epizyme

$21.41 /

+0.94 (+4.59%)

, FOMX

Foamix

$3.61 /

+0.075 (+2.12%)

, IMGN

ImmunoGen

$4.44 /

+0.05 (+1.14%)

, LLY

Eli Lilly

$126.31 /

-2.955 (-2.29%)

, MORF

Morphic Holding

$15.80 /

+0.12 (+0.77%)

, MSON

Misonix

$13.91 /

-0.43 (-3.00%)

, JNJ

Johnson & Johnson

$134.35 /

-4.61 (-3.32%)

, HZNP

Horizon Therapeutics

$34.24 /

+0.21 (+0.62%)

, GILD

Gilead

$69.37 /

-3.29 (-4.53%)

, EW

Edwards Lifesciences

$204.43 /

-8.63 (-4.05%)

, DVAX

Dynavax

$3.95 /

-0.11 (-2.71%)

, BSX

Boston Scientific

$37.35 /

-0.54 (-1.43%)

, BMRN

BioMarin

$90.34 /

+0.48 (+0.53%)

, BLUE

Bluebird Bio

$72.38 /

+5.28 (+7.87%)

, BIIB

Biogen

$308.58 /

-1.29 (-0.42%)

, CERS

Cerus

$5.12 /

-0.05 (-0.97%)

, HARP

Harpoon Therapeutics

$15.19 /

+0.94 (+6.60%)

, IRWD

Ironwood

$12.04 /

+0.135 (+1.13%)

, JAZZ

Jazz Pharmaceuticals

$114.98 /

+1.86 (+1.64%)

, MRNA

Moderna

$25.93 /

-0.23 (-0.88%)

, ZTS

Zoetis

$133.07 /

-0.88 (-0.66%)

, XOMA

Xoma

$24.00 /

+0.32 (+1.35%)

, TECH

Bio-Techne

$189.07 /

-4.51 (-2.33%)

, TMO

Thermo Fisher

$290.75 /

-7.41 (-2.49%)

, SEEL

Seelos Therapeutics

$0.87 /

+0.0342 (+4.07%)

, PIRS

Pieris Pharmaceuticals

$3.11 /

-0.03 (-0.96%)

, PFE

Pfizer

$33.44 /

-0.68 (-1.99%)

, PBYI

Puma Biotechnology

$10.76 /

+0.74 (+7.39%)

, NLTX

Neoleukin Therapeutics

$9.83 /

-0.32 (-3.15%)

, OXFD

Oxford Immunotec

$13.19 /

-0.31 (-2.30%)

, RYTM

Rhythm Pharmaceuticals

$18.97 /

+0.82 (+4.52%)

40th Annual Healthcare…

40th Annual Healthcare Conference will be held in Boston on March 2-4.

ShowHide Related Items >><<
A Agilent
$76.99 /

-0.59 (-0.76%)

02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/19/20 Piper Sandler
Agilent price target raised to $96 from $86 at Piper Sandler
02/06/20 Cowen
Developments in Agilent-Twist dispute could mean settlement imminent, says Cowen
ABBV AbbVie
$85.27 /

-0.065 (-0.08%)

02/27/20 Barclays
AbbVie initiated with an Equal Weight at Barclays
02/18/20 Cowen
AbbVie price target raised to $105 from $98 at Cowen
02/14/20 Piper Sandler
Piper says Ubrelvy prescription trajectory bodes well for Biohaven's rimegepant
02/11/20 SunTrust
Allergan price target raised to $202 from $194 at SunTrust
ADRO Aduro Biotech
$3.06 /

+0.11 (+3.73%)

01/10/20 Cowen
Aduro downgraded to Market Perform on limited visibility at Cowen
01/10/20 Cowen
Aduro Biotech downgraded to Market Perform from Outperform at Cowen
12/18/19 H.C. Wainwright
Aduro Biotech price target lowered to $4 from $7 at H.C. Wainwright
12/18/19 William Blair
Aduro Biotech downgraded to Market Perform from Outperform at William Blair
ALXN Alexion
$93.69 /

+1.56 (+1.69%)

02/25/20 Citi
Alexion loses catalyst with removal of ABY-039, says Citi
02/03/20 Nomura Instinet
Alexion price target lowered to $133 from $165 at Nomura Instinet
01/31/20 Baird
Alexion price target lowered to $140 from $165 at Baird
01/31/20 RBC Capital
Alexion reinstated with Outperform rating after Achillion acquisition
BBIO BridgeBio
$31.75 /

+1.26 (+4.13%)

02/19/20
Fly Intel: Top five analyst initiations
02/19/20 Mizuho
Mizuho starts BridgeBio with Buy rating, $51 price target
02/18/20 Mizuho
BridgeBio initiated with a Buy at Mizuho
01/07/20 Raymond James
BridgeBio price target raised to $40 from $36 at Raymond James
CTMX CytomX Therapeutics
$6.73 /

-0.39 (-5.48%)

02/27/20 Piper Sandler
CytomX Therapeutics heading for platform validation, says Piper Sandler
02/24/20 H.C. Wainwright
CytomX partner's Phase 2 initiation triggers milestone, says H.C. Wainwright
11/20/19 Guggenheim
Guggenheim starts CytomX Therapeutics with Buy rating, $16 price target
11/19/19 Guggenheim
CytomX Therapeutics initiated with a Buy at Guggenheim
EPZM Epizyme
$21.41 /

+0.94 (+4.59%)

02/25/20 H.C. Wainwright
Epizyme price target raised to $36 from $25 at H.C. Wainwright
02/24/20 Jefferies
Epizyme, Blueprint among cancer companies that fit M&A criteria, says Jefferies
01/24/20 Cowen
Epizyme price target raised to $36 from $18 at Cowen
01/24/20 SVB Leerink
SVB Leerink moving to the sidelines on Epizyme after Tazverik approval
FOMX Foamix
$3.61 /

+0.075 (+2.12%)

10/21/19 H.C. Wainwright
Foamix price target raised to $11 from $10 at H.C. Wainwright
10/16/19 Barclays
Barclays likes Foamix setup into October 20 FDA action date
10/08/19 Cantor Fitzgerald
Cantor reiterates Overweight on Foamix ahead of FMX101 PDUFA
06/11/19 Barclays
Foamix initiated with an Overweight at Barclays
IMGN ImmunoGen
$4.44 /

+0.05 (+1.14%)

12/17/19 H.C. Wainwright
ImmunoGen price target hiked to $9 after 'compelling' advance at H.C. Wainwright
09/29/19 Piper Sandler
Biomarker screening reason for ImmunoGen FORWARD I failure, says Piper Jaffray
05/15/19 H.C. Wainwright
H.C. Wainwright says 'wrong again' about ImmunoGen, lowers price target to $4
05/15/19 Guggenheim
ImmunoGen downgraded to Neutral from Buy at Guggenheim
LLY Eli Lilly
$126.31 /

-2.955 (-2.29%)

02/27/20 Barclays
Eli Lilly initiated with an Overweight at Barclays
02/18/20 Piper Sandler
Xeris Pharmaceuticals initiated with an Overweight at Piper Sandler
02/10/20 William Blair
William Blair sees little change to sentiment for aducanumab after DIAN-TU fails
02/05/20 Mizuho
Eli Lilly initiated with a Neutral at Mizuho
MORF Morphic Holding
$15.80 /

+0.12 (+0.77%)

07/22/19 Jefferies
Morphic Holding initiated with a Buy at Jefferies
07/22/19 Wells Fargo
Morphic Holding initiated with an Outperform at Wells Fargo
07/22/19 BMO Capital
Morphic Holding initiated with an Outperform at BMO Capital
MSON Misonix
$13.91 /

-0.43 (-3.00%)

12/31/19 Craig-Hallum
Misonix's amended credit line removes capital needs questions, says Craig-Hallum
08/15/19 Canaccord
Misonix price target raised to $30 from $24 at Canaccord
06/12/19
Fly Intel: Top five analyst initiations
06/12/19 BTIG
Misonix initiated with a Buy at BTIG
JNJ Johnson & Johnson
$134.35 /

-4.61 (-3.32%)

03/02/20 Wells Fargo
Baxter, J&J best positioned to weather coronavirus spread, says Wells Fargo
01/27/20 Credit Suisse
Johnson & Johnson price target raised to $170 from $163 at Credit Suisse
01/21/20 SVB Leerink
SVB Leerink bearish on Arrowhead, initiates with an Underperform
01/10/20 BWS Financial
Anika acquisitions set up direct competition with partner, says BWS Financial
HZNP Horizon Therapeutics
$34.24 /

+0.21 (+0.62%)

02/21/20 Cantor Fitzgerald
Selecta positioned for 50%-100% rally on positive data, says Cantor Fitzgerald
01/22/20 BMO Capital
Horizon Therapeutics price target raised to $46 from $40 at BMO Capita
01/22/20 Guggenheim
Horizon's label for Tepezza 'broad and incredibly clean,' says Guggenheim
01/14/20 JMP Securities
Horizon Therapeutics price target raised to $47 from $38 at JMP Securities
GILD Gilead
$69.37 /

-3.29 (-4.53%)

02/28/20 Benchmark
Ligand a 'coronavirus play in the making,' says Benchmark
02/28/20 Mizuho
Over 100% oncology buyout premiums suggestive of Forty Seven deal, says Mizuho
02/28/20 DZ Bank
Gilead downgraded to Hold from Buy at DZ Bank
02/27/20 Barclays
Gilead initiated with an Underweight at Barclays
EW Edwards Lifesciences
$204.43 /

-8.63 (-4.05%)

02/12/20 Goldman Sachs
Edwards Lifesciences initiated with a Neutral at Goldman Sachs
01/31/20 Piper Sandler
Edwards Lifesciences price target raised to $270 from $262 at Piper Sandler
01/10/20 Wells Fargo
Wells says PTAB ruling of 'zero importance' to bigger Abbott-Edwards fight
01/10/20
Fly Intel: Top five analyst upgrades
DVAX Dynavax
$3.95 /

-0.11 (-2.71%)

10/18/19 H.C. Wainwright
Dynavax initiated with a Buy at H.C. Wainwright
07/10/19 Cantor Fitzgerald
Dynavax upgraded to Overweight from Neutral at Cantor Fitzgerald
06/18/19 BMO Capital
VBI Vaccines price target lowered to $5 from $12 at BMO Capital
05/24/19 RBC Capital
Dynavax price target lowered to $13 from $19 at RBC Capital
BSX Boston Scientific
$37.35 /

-0.54 (-1.43%)

02/12/20 Goldman Sachs
Boston Scientific initiated with a Neutral at Goldman Sachs
02/05/20 Piper Sandler
Piper Sandler constructive on Boston Scientific given guidance, new product flow
01/17/20 Piper Sandler
FDA recommendation a 'solid tailwind' for Boston Scientific, says Piper Sandler
01/15/20 Cowen
Boston Scientific weakness a buying opportunity, says Cowen
BMRN BioMarin
$90.34 /

+0.48 (+0.53%)

02/28/20 Citi
BioMarin price target raised to $105 from $95 at Citi
02/27/20 Oppenheimer
BioMarin price target raised to $88 from $80 at Oppenheimer
02/26/20 Piper Sandler
BioMarin firing on all cylinders, says Piper Sandler
02/24/20 Chardan
Homology Medicines initiated with a Buy at Chardan
BLUE Bluebird Bio
$72.38 /

+5.28 (+7.87%)

02/20/20 Oppenheimer
Bluebird Bio price target lowered to $128 from $135 at Oppenheimer
02/19/20 Raymond James
Bluebird Bio downgraded to Market Perform from Strong Buy at Raymond James
02/19/20 Piper Sandler
Bluebird pushed Biologics License Application to second half, says Piper Sandler
02/03/20 Evercore ISI
Bluebird Bio upgraded to Outperform on undervalued assets at Evercore ISI
BIIB Biogen
$308.58 /

-1.29 (-0.42%)

02/28/20 William Blair
Biogen deal with Sangamo unlikely to have near-term impact, says William Blair
02/27/20 Barclays
Biogen initiated with an Overweight at Barclays
02/24/20 Jefferies
Jefferies starts Denali Therapeutics at Buy ahead of 'lots of catalysts in 2020'
CERS Cerus
$5.12 /

-0.05 (-0.97%)

02/26/20 BTIG
Cerus initiated with a Buy at BTIG
01/23/20 Cowen
Cowen encouraged by Cerus data on Intercept in light of new coronavirus
11/13/19 BTIG
Cerus upgraded to Buy from Neutral at BTIG
08/28/19
Fly Intel: Top five analyst initiations
HARP Harpoon Therapeutics
$15.19 /

+0.94 (+6.60%)

02/28/20
Fly Intel: Top five analyst initiations
02/27/20 SunTrust
Harpoon Therapeutics initiated with a Buy at SunTrust
02/03/20
Fly Intel: Top five analyst initiations
02/03/20 H.C. Wainwright
Harpoon Therapeutics initiated with a Buy at H.C. Wainwright
IRWD Ironwood
$12.04 /

+0.135 (+1.13%)

08/05/19 Credit Suisse
Ironwood assumed with a Neutral at Credit Suisse
07/10/19 Credit Suisse
Ironwood assumed with a Neutral at Credit Suisse
03/27/19 Morgan Stanley
Morgan Stanley upgrades Ironwood to Equal Weight on more stable Linzess growth
03/27/19 Morgan Stanley
Ironwood upgraded to Equal Weight from Underweight at Morgan Stanley
JAZZ Jazz Pharmaceuticals
$114.98 /

+1.86 (+1.64%)

02/26/20 RBC Capital
Jazz Pharmaceuticals price target lowered to $164 from $184 at RBC Capital
02/26/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $154 from $183 at Oppenheimer
02/26/20 Cowen
Jazz Pharmaceuticals lowered his price target to $165 from $200 at Cowen
02/26/20 Piper Sandler
Jazz Pharmaceuticals price target lowered to $129 from $142 at Piper Sandler
MRNA Moderna
$25.93 /

-0.23 (-0.88%)

02/28/20 Piper Sandler
Moderna has five potential mRNA rare disease blockbusters, says Piper Sandler
02/27/20 JPMorgan
Moderna price target raised to $32 from $24 at JPMorgan
02/27/20 Roth Capital
Moderna price target raised to $33 from $24 at Roth Capital
02/26/20 Piper Sandler
Piper Sandler backs rating on Moderna after coronavirus vaccine shipped
ZTS Zoetis
$133.07 /

-0.88 (-0.66%)

02/14/20 SunTrust
Zoetis price target raised to $145 from $130 at SunTrust
01/10/20 Raymond James
Zoetis' premium valuation vs. peers likely to persist, says Raymond James
01/09/20 Raymond James
Zoetis initiated with a Market Perform at Raymond James
12/19/19 BofA
Elanco upgraded to Buy from Neutral at BofA/Merrill
XOMA Xoma
$24.00 /

+0.32 (+1.35%)

TECH Bio-Techne
$189.07 /

-4.51 (-2.33%)

02/24/20 Eight Capital
Bio-Techne downgraded to Neutral from Buy at Eight Capital
01/08/20 Stephens
Bio-Techne resumed with an Overweight at Stephens
01/07/20 Wells Fargo
Bio-Techne initiated with an Equal Weight at Wells Fargo
01/06/20 Citi
Bio-Techne initiated with a Neutral at Citi
TMO Thermo Fisher
$290.75 /

-7.41 (-2.49%)

02/24/20 Argus
Thermo Fisher price target raised to $370 from $340 at Argus
01/31/20 BTIG
Thermo Fisher price target raised to $372 from $342 at BTIG
01/31/20 Baird
Thermo Fisher weakness a buying opportunity, says Baird
01/31/20 Citi
Thermo Fisher earnings selloff a buying opportunity, says Citi
SEEL Seelos Therapeutics
$0.87 /

+0.0342 (+4.07%)

11/18/19 H.C. Wainwright
Seelos Therapeutics price target lowered to $2 from $4 at H.C. Wainwright
11/14/19 Benchmark
Seelos Therapeutics initiated with a Speculative Buy at Benchmark
05/14/19 Roth Capital
Seelos Therapeutics initiated with a Buy at Roth Capital
05/10/19 H.C. Wainwright
Seelos Therapeutics initiated with a Buy at H.C. Wainwright
PIRS Pieris Pharmaceuticals
$3.11 /

-0.03 (-0.96%)

01/27/20 H.C. Wainwright
Pieris Pharmaceuticals price target raised to $9 from $7 at H.C. Wainwright
07/30/19 Baird
Pieris Pharmaceuticals downgraded to Neutral from Outperform at Baird
07/29/19 William Blair
Updates 'very positive' for upcoming Pieris presentation, says William Blair
05/14/19 Baird
Pieris Pharmaceuticals initiated with an Outperform at Baird
PFE Pfizer
$33.44 /

-0.68 (-1.99%)

02/27/20 Standpoint Research
Pfizer upgraded to Buy from Hold at Standpoint Research
02/27/20 Barclays
Pfizer initiated with an Equal Weight at Barclays
02/12/20 Baird
Exact Sciences weakness would be buying opportunity, says Baird
02/11/20 Roth Capital
GlycoMimetics termination notice from Pfizer no surprise, says Roth Capital
PBYI Puma Biotechnology
$10.76 /

+0.74 (+7.39%)

12/06/19 H.C. Wainwright
Puma Biotechnology initiated with a Buy at H.C. Wainwright
11/08/19 Cantor Fitzgerald
Puma Biotechnology price target lowered to $14 from $20 at Cantor Fitzgerald
11/07/19 RBC Capital
Puma Biotechnology price target lowered to $13 from $23 at RBC Capital
11/07/19 Barclays
Puma Biotechnology price target lowered to $6 from $9 at Barclays
NLTX Neoleukin Therapeutics
$9.83 /

-0.32 (-3.15%)

02/18/20
Fly Intel: Top five analyst initiations
02/18/20 Guggenheim
Guggenheim starts Neoleukin Therapeutics at Buy with $20 price target
02/18/20 Guggenheim
Neoleukin Therapeutics initiated with a Buy at Guggenheim
01/10/20 Piper Sandler
Neoleukin Therapeutics initiated with an Overweight at Piper Sandler
OXFD Oxford Immunotec
$13.19 /

-0.31 (-2.30%)

09/24/19 Cowen
Oxford Immunotec company sale may make sense, says Cowen
09/18/19 Piper Sandler
Oxford Immunotec's new approach to China could boost sales, says Piper Jaffray
03/12/19 Baird
Oxford Immunotec's 2019 guidance seems 'conservative,' says Baird
03/12/19 Piper Sandler
Oxford Immunotec well positioned for strong 2019 transition, says Piper Jaffray
RYTM Rhythm Pharmaceuticals
$18.97 /

+0.82 (+4.52%)

01/08/20 Goldman Sachs
Rhythm Pharmaceuticals initiated with a Sell at Goldman Sachs
07/12/19 Stifel
Rhythm Pharmaceuticals upgraded to Buy from Hold at Stifel
03/13/19
Fly Intel: Top five analyst initiations
03/13/19 Ladenburg
Ladenburg starts Rhythm Pharmaceuticals with Buy rating, $43 price target

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.